|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...115116117118119120121122123124125...156157» |
- | Trial completion: A Study on the Prevalence of the Modified Citrullinated Vimentin Anti-body (Anti-MCV) in an Irish Rheumatoid Arthritis (RA) Population and to Assess the Impact of Anti-MCV and the Anti-cyclic-citrullinated Peptide Antibody (Anti-CCP) Status on the Management of Irish Patients With Early RA (clinicaltrials.gov) - Aug 15, 2013
P=N/A, N=35, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed
- ||| tibulizumab (ZB-106) / Zura Bio
New P1 trial: A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Aug 15, 2013
P1, N=51, Recruiting, Sponsor: Eli Lilly and Company
- | Lantus (insulin glargine) / Sanofi
Trial completion: Repeated Dose Study With a New Insulin Glargine Formulation and Lantus (clinicaltrials.gov) - Aug 15, 2013
P1, N=20, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Recruiting --> Completed
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Aug 14, 2013
P1, N=36, Completed, Sponsor: Novo Nordisk
- Enrollment open: A Non-drug Study Profiling Cutaneous Lupus (clinicaltrials.gov) - Aug 11, 2013
P0, N=30, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| tabalumab (LY2127399) / Eli Lilly
Enrollment closed: A Study of LY2127399 in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) - Aug 11, 2013
P3, N=1140, Active, not recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Aug 11, 2013
P2, N=131, Active, not recruiting, Sponsor: Lawrence S. Morse, MD
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Enrollment change: Fingolimod -Response According to Coping - Evaluation (clinicaltrials.gov) - Aug 8, 2013
P4, N=189, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting N=250 --> 189
- |||| Trial completion: Fingolimod -Response According to Coping - Evaluation (clinicaltrials.gov) - Aug 8, 2013
P4, N=189, Completed, Sponsor: Novartis Pharmaceuticals
N=250 --> 189 Recruiting --> Completed
- Tresiba (insulin degludec) / Novo Nordisk
Enrollment change: A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin Glargine (clinicaltrials.gov) - Aug 8, 2013
P1, N=40, Completed, Sponsor: Novo Nordisk
Recruiting --> Completed N=17 --> 40
- | Lantus (insulin glargine) / Sanofi
Trial completion: Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Aug 8, 2013
P1, N=50, Completed, Sponsor: Sanofi
N=17 --> 40 Active, not recruiting --> Completed
- Clinical: Effectiveness and Safety of Physical Exercises in the Improvement of the Sleep Quality. Regarding Rheumatoid Arthritis (clinicaltrials.gov) - Aug 7, 2013
P=N/A, N=31, Recruiting, Sponsor: Federal University of São Paulo
- |||||| dalfampridine / Generic mfg.
Enrollment open: A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis (clinicaltrials.gov) - Aug 7, 2013
P3, N=128, Recruiting, Sponsor: Biogen Idec
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | New P1 trial: Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia (clinicaltrials.gov) - Aug 7, 2013
P1, N=12, Completed, Sponsor: Animas Corporation
- Rituxan (rituximab) / Roche
Enrollment open: Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia (clinicaltrials.gov) - Aug 7, 2013
P=N/A, N=100, Recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- ||| Enrollment closed: CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM) (clinicaltrials.gov) - Aug 7, 2013
P4, N=400, Active, not recruiting, Sponsor: Halozyme Therapeutics
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- || New P3 trial: A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis (clinicaltrials.gov) - Aug 6, 2013
P3, N=600, Recruiting, Sponsor: Department of Veterans Affairs
- Enrollment open: PSO4: Outpatient Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension in Children (clinicaltrials.gov) - Aug 6, 2013
P2, N=120, Recruiting, Sponsor: In Home Closed Loop Study Group
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Trial completion: Outpatient Pump Shutoff Pilot Feasibility and Efficacy Study (clinicaltrials.gov) - Aug 6, 2013
P2, N=49, Completed, Sponsor: In Home Closed Loop Study Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial initiation date: Primary TKA Cruciate Retaining vs Cruciate Substituting With Rotating Platform Knee Prostheses (clinicaltrials.gov) - Aug 5, 2013
P=N/A, N=399, Terminated, Sponsor: DePuy Orthopaedics
Active, not recruiting --> Completed Initiation date: Oct 2000 --> Feb 2001
- armodafinil / Generic mfg.
Trial completion: Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS) (clinicaltrials.gov) - Aug 5, 2013
P2/3, N=33, Completed, Sponsor: University of Missouri, Kansas City
Initiation date: Oct 2000 --> Feb 2001 Enrolling by invitation --> Completed
- New P1 trial: GABA-PK: Pharmacokinetics Study of Gamma-aminobutyric Acid (clinicaltrials.gov) - Aug 5, 2013
P1, N=12, Recruiting, Sponsor: Huashan Hospital
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment open: U-Act-After: An Observational Study on Long-Term Efficacy of Tight Control RoActemra/Actemra (Tocilizumab) and/or Methotrexate in Patients With Early Rheumatoid Arthritis Who Have Participated in the U-Act-Early Study (ML22497) (clinicaltrials.gov) - Aug 5, 2013
P=N/A, N=300, Recruiting, Sponsor: Hoffmann-La Roche
Enrolling by invitation --> Completed Not yet recruiting --> Recruiting
- | DegludecPlus (insulin degludec/insulin aspart) / Novo Nordisk
Trial completion: A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Aug 5, 2013
P1, N=33, Completed, Sponsor: Novo Nordisk
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| dalfampridine / Generic mfg.
New P3 trial: A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis (clinicaltrials.gov) - Aug 4, 2013
P3, N=128, Recruiting, Sponsor: Biogen Idec
- | Enrollment open: A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis (clinicaltrials.gov) - Aug 4, 2013
P3, N=600, Recruiting, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Enrollment closed: BONARTH: Benefit of Orthopedic Navigation in the ARThroplasty of the Hip (clinicaltrials.gov) - Aug 4, 2013
P4, N=89, Active, not recruiting, Sponsor: Aesculap AG
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Enrollment open: GABA-PK: Pharmacokinetics Study of Gamma-aminobutyric Acid (clinicaltrials.gov) - Aug 4, 2013
P1, N=12, Recruiting, Sponsor: Huashan Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- tilarginine (L-NMMA) / Arginox Pharma, Houston Methodist Research Institute
Enrollment open: Diameter Changes of Retinal Vessels During Hypoxia (clinicaltrials.gov) - Aug 4, 2013
P=N/A, N=60, Recruiting, Sponsor: University of Aarhus
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial completion: Very-Low-Density-Lipoprotein-Triglyceride(VLDL-TG) Metabolism During Acute Hyperglycemia (clinicaltrials.gov) - Aug 4, 2013
P=N/A, N=8, Completed, Sponsor: University of Aarhus
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial suspension: Interest of a Standardized Monitoring of Rheumatoid Arthritis: The COMEDRA Trial (clinicaltrials.gov) - Aug 1, 2013
P=N/A, N=970, Suspended, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed Active, not recruiting --> Suspended
- | Trial completion: TRIFRA: Efficacy and Safety of Tripterygium Wilfordii in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Aug 1, 2013
P2/3, N=201, Completed, Sponsor: Peking Union Medical College Hospital
Active, not recruiting --> Suspended Recruiting --> Completed
- New P1 trial: Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages (clinicaltrials.gov) - Aug 1, 2013
P1, N=6, Completed, Sponsor: Profil Institut f
- | Rituxan (rituximab) / Roche
Trial completion: MAINRITSAN: Efficacy Study of Two Treatments in the Remission of Vasculitis (clinicaltrials.gov) - Aug 1, 2013
P3, N=117, Completed, Sponsor: Assistance Publique - H
Recruiting --> Completed Active, not recruiting --> Completed
- | meloxicam / Generic mfg.
Trial initiation date: This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets. (clinicaltrials.gov) - Jul 31, 2013
P2, N=28, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Initiation date: Jan 2013 --> Sep 2013
- | Tekturna (aliskiren) / PDL
Enrollment change, Combination therapy: Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease (clinicaltrials.gov) - Jul 30, 2013
P4, N=46, Completed, Sponsor: Columbia University
Initiation date: Jan 2013 --> Sep 2013 N=120 --> 46
- | Tekturna (aliskiren) / PDL
Trial completion, Combination therapy: Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease (clinicaltrials.gov) - Jul 30, 2013
P4, N=46, Completed, Sponsor: Columbia University
N=120 --> 46 Active, not recruiting --> Completed
- hydroxychloroquine / Generic mfg.
Enrollment change: RA PLUS: Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis (clinicaltrials.gov) - Jul 30, 2013
P3, N=23, Completed, Sponsor: Brigham and Women's Hospital
Active, not recruiting --> Completed N=45 --> 23
- Enrollment open: The VIGORous Physical Activity for Glycaemic Control in Type 1 Diabetes (VIGOR) Trial (clinicaltrials.gov) - Jul 30, 2013
P4, N=70, Recruiting, Sponsor: University of Manitoba
N=45 --> 23 Not yet recruiting --> Recruiting
- hydroxychloroquine / Generic mfg.
Trial completion: RA PLUS: Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis (clinicaltrials.gov) - Jul 30, 2013
P3, N=23, Completed, Sponsor: Brigham and Women's Hospital
Not yet recruiting --> Recruiting Recruiting --> Completed
- leflunomide / Generic mfg.
Enrollment open: A Clinical Study of Xin'an Medicine in the Treatment of Bi Syndrome (clinicaltrials.gov) - Jul 29, 2013
P=N/A, N=304, Recruiting, Sponsor: The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| Inflectra (infliximab biosimilar IV) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
Trial completion: An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1 (clinicaltrials.gov) - Jul 29, 2013
P3, N=302, Completed, Sponsor: Celltrion
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Awiqli (insulin icodec) / Novo Nordisk
Trial completion: A Trial Investigating the Safety, Tolerability, and Distribution and Activity in the Body of NNC0148-0000-0287 Injected Under the Skin in Healthy Subjects and in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jul 29, 2013
P1, N=70, Completed, Sponsor: Novo Nordisk
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change, Combination therapy: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis (clinicaltrials.gov) - Jul 28, 2013
P3, N=880, Active, not recruiting, Sponsor: UCB, Inc.
Active, not recruiting --> Completed N=600 --> 880
- Enrollment change: The CORRONA Treat to Target Trial: Outcomes and Feasibility in a US Population (clinicaltrials.gov) - Jul 28, 2013
P=N/A, N=530, Enrolling by invitation, Sponsor: The Consortium of Rheumatology Researchers of North America, Inc.
N=600 --> 880 N=33312 --> 530
- ||||| TNF-α kinoid / Neovacs, Debiopharm
New P2 trial: Clinical Efficacy of TNF-Kinoid in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 28, 2013
P2, N=140, Active, not recruiting, Sponsor: Neovacs
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed: An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis (clinicaltrials.gov) - Jul 28, 2013
P=N/A, N=100, Active, not recruiting, Sponsor: Genentech
N=33312 --> 530 Recruiting --> Active, not recruiting
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed, Combination therapy: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis (clinicaltrials.gov) - Jul 28, 2013
P3, N=880, Active, not recruiting, Sponsor: UCB, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion: The Role of ITGAM in Systemic Lupus Erythematosus (clinicaltrials.gov) - Jul 28, 2013
P=N/A, N=40, Completed, Sponsor: North Shore Long Island Jewish Health System
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed
- Trial initiation date: Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy (France) (clinicaltrials.gov) - Jul 28, 2013
P=N/A, N=5, Completed, Sponsor: University of Virginia
Enrolling by invitation --> Completed Initiation date: Jan 2013 --> May 2013